These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 178234)

  • 1. Immunotherapy of malignancies: current status.
    Eilber FR; Holmes EC; Morton DL; Ramming KP; Sparks FC
    AJR Am J Roentgenol; 1976 May; 126(5):1088-93. PubMed ID: 178234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
    Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
    N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonspecific immunotherapy of malignant tumors.
    Milas L; Withers HR
    Radiology; 1976 Jan; 118(1):211-8. PubMed ID: 1105663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
    Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
    Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer immunotherapy.
    Richman SP; Gutterman JU; Hersh EM
    Can Med Assoc J; 1979 Feb; 120(3):322-4, 329. PubMed ID: 371776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCG immunotherapy of malignant melanoma: summary of a seven-year experience.
    Morton DL; Eilber FR; Holmes EC; Hunt JS; Ketcham AS; Silverstein MJ; Sparks FC
    Ann Surg; 1974 Oct; 180(4):635-43. PubMed ID: 4412271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of sarcomas.
    Leventhal BG
    Natl Cancer Inst Monogr; 1981 Apr; (56):183-7. PubMed ID: 6170891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of BCG and C. parvum treatment on human melanoma xenografts.
    Garrett AJ; Reeson DE; Osborn TW; Boulger LR
    Dev Biol Stand; 1977 Apr 13-15; 38():363-8. PubMed ID: 608525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inconsistent response of B16 melanoma to BCG immunotherapy.
    Kreider JW; Bartlett GL; Purnell DM
    J Natl Cancer Inst; 1976 Apr; 56(4):803-10. PubMed ID: 1255799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of malignancy in humans. Current status.
    Holmes EC; Eilber FR; Morton DL
    JAMA; 1975 Jun; 232(10):1052-5. PubMed ID: 236402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Possibilities of immunotherapy in malignant melanoma].
    Lewis MG
    Hautarzt; 1978 Dec; 29(12):619-24. PubMed ID: 363650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant immunotherapy.
    Goodnight JE; Morton DL
    Int Adv Surg Oncol; 1978; 1():53-83. PubMed ID: 399764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in malignant melanomaa.
    Homes EC; Morton DL; Eilber FR; Golub SE; Sulit HL
    Natl Cancer Inst Monogr; 1976 Nov; 44():85-6. PubMed ID: 799763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteosarcoma. Results of treatment employing adjuvant immunotherapy.
    Eilber FR; Townsend C; Morton DL
    Clin Orthop Relat Res; 1975 Sep; (111):94-100. PubMed ID: 1057467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response and non-specific immunotherapy in melanoma.
    El-Domeiri AA
    Ann R Coll Surg Engl; 1978 Mar; 60(2):117-20. PubMed ID: 637492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
    El-Domeiri AA; Das Gupta TK; Trippon M; Simo C; Sabet TY; Crispen R
    Surg Gynecol Obstet; 1978 Feb; 146(2):230-2. PubMed ID: 622668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
    Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
    Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunotherapy in superficial bladder carcinoma].
    Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ
    Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.